Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06343636 | A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease | PHASE1 | COMPLETED | 115 | — | — | Sep 22, 2023 | Jan 10, 2025 | Feb 7, 2025 | 3 | United States, Australia |
To evaluate the safety and tolerability of VG-3927
| Arm | Type | Description |
|---|---|---|
| Single and Multiple Ascending Dose | EXPERIMENTAL | Ascending single doses and multiple doses for healthy volunteers. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Alzheimer's Disease | EXPERIMENTAL | Single Dose Open-label |
| Name | Type | Description |
|---|---|---|
| VG-3927 | DRUG | Dose Escalation |
| Placebo | DRUG | Dose Escalation |
Inclusion Criteria: * The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation * The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent Exclusion Criteria: * The partici...